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Abstract
Background:  Screening for organ rejection is a critical component of care for patients who have
undergone heart transplantation. Endomyocardial biopsy is the gold standard screening tool, but non-
invasive alternatives are needed. Cardiovascular magnetic resonance (CMR) is well suited to provide an
alternative to biopsy because of its ability to quantify ventricular function, morphology, and characterize
myocardial tissue. CMR is not widely used to screen for heart transplant rejection, despite many trials
supporting its use for this indication. This review summarizes the different CMR sequences that can detect
heart transplant rejection as well as the strengths and weaknesses of their application.
Results: T2 quantification by spin echo techniques has been criticized for poor reproducibility, but
multiple studies show its utility in screening for rejection. Human and animal data estimate that T2
quantification can diagnose rejection with sensitivities and specificities near 90%. There is also a suggestion
that T2 quantification can predict rejection episodes in patients with normal endomyocardial biopsies.
T1 quantification has also shown association with biopsy proven rejection in a small number of trials. T1
weighted gadolinium early enhancement appeared promising in animal data, but has had conflicting results
in human trials. Late gadolinium enhancement in the diagnosis of rejection has not been evaluated.
CMR derived measures of ventricular morphology and systolic function have insufficient sensitivity to
diagnose mild to moderate rejection. CMR derived diastolic function can demonstrate abnormalities in
allografts compared to native human hearts, but its ability to diagnose rejection has not yet been tested.
There is promising animal data on the ability of iron oxide contrast agents to illustrate the changes in
vascular permeability and macrophage accumulation seen in rejection. Despite good safety data, these
contrast agents have not been tested in the human heart transplant population.
Conclusion: T2 quantification has demonstrated the best correlation to biopsy proven heart transplant
rejection. Further studies evaluating diastolic function, late gadolinium enhancement, and iron oxide
contrast agents to diagnose rejection are needed. Future studies should focus on combining multiple CMR
measures into a transplant rejection scoring system which would improve sensitivity and possibly reduce,
if not eliminate, the need for endomyocardial biopsy.
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Background
Heart transplantation is a life saving therapy for select
individuals with end-stage heart failure[1]. Despite signif-
icant advances in anti-rejection therapy, allograft rejection
remains a leading cause of mortality with one in four
transplant patients dying within five years after surgery
[2,3].
Diagnosis and Screening for Acute Cellular Rejection
Acute cellular rejection is the most common form of heart
transplant rejection. Cardiac transplant recipients have
between one and three episodes of acute cellular rejection
within the first year after transplantation [3]. Moreover,
the incidence of cellular rejection requiring treatment is
estimated to be 8% and 4% in the first and fifth year post
surgery, respectively [3]. Cellular rejection is a host T-cell-
mediated reaction to donor antigens resulting in myocar-
dial infiltration with lymphocytes and macrophages,
myocardial edema, and myocyte necrosis [4].
Since the early 1970s the gold standard for detection of
cellular cardiac rejection has been regular transjugular
endomyocardial biopsy [5]. Myocardial tissue obtained
from biopsy undergoes histologic grading for severity of
cellular rejection as well as immunologic staining to
assess for the presence of humoral rejection [6]. Endomy-
ocardial biopsy is uncomfortable for patients and has the
potential for rare, but life threatening complications [7,8].
In addition, random biopsy sampling often misses the
patchy foci of rejection[9] and there is significant variabil-
ity in the reporting of histologic specimens [10,11].
Despite these limitations endomyocardial biopsy remains
the principle method for rejection screening. It is an
important clinical undertaking to find an accurate and less
invasive alternative to endomyocardial biopsy for the
diagnosis of cardiac transplant rejection.
In the early stages of acute heart transplant rejection the
myocardium is inflamed, however, there are often little or
no symptoms, nor gross evidence of cardiac dysfunction
[4,12,13]. Serial echocardiographic measurements of left
ventricular volumes, ejection fraction, wall thickness and
mass are too insensitive to screen for transplant rejection
in the era of contemporary antirejection therapy [14].
During acute rejection diastolic dysfunction precedes
systolic dysfunction [15]. Doppler measures of myocar-
dial diastolic properties such as isovolumic relaxation
time (IVRT) [13,16,17], Index of Myocardial performance
[18], and Peak Filling Rate [19] have shown correlation to
acute rejection though not with uniform consistency [20].
Cardiovascular magnetic resonance (CMR) is the gold
standard imaging modality for evaluation of ventricular
volumes, morphology, and mass due to superior image
quality as compared to echocardiography and nuclear
modalities [21-23]. CMR can also measure ventricular
diastolic properties such as regional myocardial tissue
velocity, strain and rotation [24]. CMR also has proven
utility in detecting myocardial inflammation in disease
states such as myocardial infarction [25], viral myocarditis
[26], Tako-Tsubo cardiomyopathy [27], dilated cardiomy-
opathy [28], as well as heart transplant rejection in both
animal [29-31] and human [16,20,32,33] models. The
ability of CMR to characterize ventricular morphology,
systolic function, diastolic function, and myocardial
inflammation makes it an excellent candidate to non-
invasively diagnose and screen for acute heart transplant
rejection.
Since the late 1980s there have been many small trials
(Table 1) comparing CMR with endomyocardial biopsy in
the diagnosis of heart transplant rejection with predomi-
nantly positive results [16,20,32-38]. Despite these find-
ings, CMR has not gained widespread use in the
surveillance and diagnosis of acute heart transplant rejec-
tion. This paper will review the animal and human data
supporting the use of CMR for the diagnosis of heart
transplant rejection and highlight potential CMR targets
for future study.
Best Studied CMR Correlates of Heart Transplant 
Rejection
T2 weighted CMR
Myocardial T2 signal intensity
Myocardial T2 signal intensity (SI) is influenced by myo-
cardial water content and can clinically detect myocardial
inflammation associated with myocarditis [26], Tako-
Tsubo cardiomyopathy [27], and acute myocardial infarc-
tion[39]. The ability of T2 SI to detect heart transplant
rejection has been inconsistent in the literature[29,35].
Aherne et al. showed in a dog model that T2 SI was ini-
tially similar between untreated allografts and non-trans-
plant controls, but by day seven, T2 SI was 66% higher in
the untreated allograft group compared to controls[29].
Smart et al., and Revel et al. found no difference in T2
weighted SI in patients with biopsy proven rejection com-
pared to those without rejection[34,38]. Notably, Smart et
al. did show that serial signal intensities for a given patient
increased with biopsy proven rejection and decreased
with anti-rejection therapy, however the specificity was
only 33%[34]. Alemnar et al. found no association
between T2 STIR values and transplant rejection in a
group of 40 transplant patients [35]. Despite its utility in
other myocardial disease states, T2 signal intensity has
shown mixed results in diagnosing heart transplant rejec-
tion.
Myocardial T2 Quantification
T2 relaxation time is the decay time constant of magnetic
signal after an excitatory pulse. T2 relaxation time is calcu-Journal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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lated by plotting the spin echo signal intensity against var-
ying echo times and is believed to lengthen in proportion
to the degree of myocardial edema (Figure 1). Long T2
relaxation times are associated with high tissue water con-
tent in models of myocardial infarction[25], myocardi-
tis[26], and animal models of acute rejection [29-31,40]
and is therefore a biologically plausible variable to detect
human heart transplant rejection.
Normal myocardial T2 relaxation times vary as a function
of magnetic field strength and measured values will
depend on whether or not an appropriate pulse sequence
for quantifying T2 has been used. The last point cannot be
stressed enough given that not all T2-weighted pulse
sequences are appropriate for obtaining accurate T2 meas-
urements. For this reason, CMR studies generally define
their own normal T2 relaxation times from a group of
controls and describe abnormal T2 relaxation as more
than two standard deviations above the mean [16,20,33].
Since 1985, there have been eleven animal trials evaluat-
ing T2 relaxation time and transplant rejection. These tri-
als have used predominantly rat and dog models and
applied a variety of imaging platforms, transplant tech-
niques and anti-rejection regimens. Nevertheless, they
demonstrated that T2 relaxation times increased with his-
tologic rejection [29,30,40-45] and ex-vivo myocardial
water content [29,30,40,41] (Table 1). Furthermore, they
also demonstrated that the prolongation of T2 relaxation
times observed in transplant rejection could be prevented
by the addition of immunosuppressive agents such as
cyclosporine [29,42].
There have been eight human trials totaling 302 patients
(521 CMR scans) comparing T2 relaxation times to trans-
plant rejection as determined by endomyocardial biopsy
(Table 2) [46-48]. Four trials showed significant correla-
tion between T2 relaxation times and transplant rejection
(Table 3) [16,20,32,33]. The two trials that did not find an
association between T2 and rejection both gated their
image acquisition to ventricular systole [36,37] which
often leads to signal loss and poor image quality [49,50].
In an early investigation, Wisenberg et al performed CMR
(0.15 T) on ten healthy volunteers to establish normal val-
ues for T2 relaxation times and compared them with those
obtained from 25 transplant patients scanned within 24
hours of endomyocardial biopsy [33]. Transplant patients
were scanned immediately following heart transplanta-
tion out to a maximum of 107 days. Patients who were
scanned more than 24 days after heart transplantation
showed significant correlation between T2 relaxation
times and endomyocardial biopsy. All patients who were
scanned in the first 24 days post transplantation had ele-
vated T2 relaxation times irrespective of their biopsy
results. After 24 days, a T2 relaxation time of > 46 ms (i.e.,
2 standard deviations above control T2 relaxation times)
achieved a sensitivity of 93% and specificity of 96% for
detecting rejection. A second control group of patients
undergoing non-transplant thoracotomy displayed T2
relaxation times that were not different from healthy vol-
unteers. This suggests that T2 relaxation times are not able
to discriminate rejecting and non-rejecting allografts in
the peri-operative period. It also suggests that there are
early causes of inflammation in heart transplantation not
Table 1: T2 values in rejecting and non-rejecting animal models of heart transplantation.
Trial Animal Model T2 (ms)
Non-rejector vs. Rejector
P value Field Strength
Walpoth et al 1998 Pig 47 +/- 6 vs. 50 +/- 6 ns 1.5 T
Kurland et al 1989 Rat 35 +/2* vs. 46 +/- 6 < 0.001 1.5 T
Sasaki et al 1987 Dog 36 vs 49 < 0.01 1.5 T
Aherne et al 1986 Dog 42 +/- 5† vs. 66 +/- 8 < 0.01 0.35 T
Tscholakoff et al 1985 Dog 36 +/- 5† vs. 58 +/- 10 < 0.005 0.35 T
Sasaguri 1985 Rat 39 vs. 53 < 0.01 Pulse spectrometer
0.5 T
Huber 1985 Rat 49 +/- 1 vs. 68 +/- 10 < 0.005 Pulse Spectrometer
0.25 T
ns = not significant
* isografts
†Non transplant controlJournal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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related to rejection. Pereira et al. have shown that in the
first week post heart transplantation, there are transient
increases in myocardial wall thickness that presumably
reflect myocardial edema and are correlated to the length
of cold ischemic time, but not to the presence of rejection
[51]. Previous work in pig models have shown significant
myocardial edema resulting from the administration of
cardio-protective solutions used during organ harvesting
[52,53]. These findings suggest that T2 relaxation times
are not able to discriminate rejecting and non-rejecting
Comparison of T2 in 2 cardiac transplant patients Figure 1
Comparison of T2 in 2 cardiac transplant patients. a) Localizing 3 chamber FISP image. b) Axial HASTE images with var-
ying echo times (TE). White square represents septal ROI used to measure signal intensity (SI). c) Plot of SI vs. TE. T2 derived 
from fitting to curve to an exponential. Patient 1: CMR T2 = 53 ms (normal). Biopsy = no rejection. Patient 2: CMR T2 = 65 ms 
(elevated). Biopsy = ISHLT grade 2R rejection.Journal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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allografts in the peri-operative period due to normal
inflammation and edema that occurs early after heart
transplantation.
In a series of studies by Marie et al., it was found that T2
relaxation times were significantly higher in patients with
International Society of Heart and Lung Transplant
(ISHLT 1990) grade 2 or 3 rejection compared to those
with less than grade 2 rejection (60 ms vs. 51 ms, p =
0.0001) [16,20]. The sensitivity in these studies was 89%
and specificity was 75% and 91%, respectively [16,20].
Marie et al. also demonstrated that T2 relaxation times
normalized following treatment of the rejection episode
(60 ms vs. 49 ms) [16]. In a subgroup analysis[16],
patients categorized as 'false positive' (i.e. elevated T2
relaxation time with no biopsy evidence of rejection) were
significantly more likely to develop rejection in the subse-
quent three months than patients with both normal CMR
and normal biopsy results (Sensitivity 63%, Specificity
78%).
Any assessment of diagnostic accuracy is predicated on the
accuracy of the 'Gold Standard'. The utility of endomyo-
cardial biopsy is clear, however, its diagnostic accuracy is
Table 2: Human Trials comparing endomyocardial biopsy and CMR in the diagnosis of acute heart transplant rejection
Author Year n Scans Positive biopsies Age Time from Txplant Delay to CMR Histologic Grading
Almenar L 2003 40 64 - 51 +/- 13 yrs 13–3725 days - Defined*
Marie P.Y 2001 68 123 19 51 +/- 13 yrs 8 +/- 11 mth <4 days ISHLT[47]
Marie P.Y 1998 52 52 9 51 +/- 14 yrs 32 +/- 42 mth < 1 wk ISHLT[47]
Smart F.W. 1993 8 33 3 - 1–7 mth <24 hrs McAlister[48]
Mousseaux E 1993 39 39 7 52 (18–69) yrs 7 d–5 yrs <48 hrs ISHLT[47]
Revel 1989 29 33 8† 45 (11–60) yrs 3 wk-5 yrs <3 days Billingham[46]
Lund G 1988 9 35 2 5 mos – 59 yrs 1–13 wks <24 hrs Not stated
Wisenberg G 1987 25 62 16 14–57 yrs 9–107 days <24 hrs Defined‡
Totals 302 521 75
- Not available
* ≥1 focus of myocyte necrosis
† rejection defined as Billingham grade 1 or greater
‡ lymphocytic infiltrate with myocytolysis
Table 3: T2 values by ISHLT(1990) grade of rejection
Trial Mean T2 Relaxation Times
Control Grade 0 Grade 1 Grade 2 Grade 3
Wisenberg et al
(1987)




- 62 +/- 6* -
Lund et al (1988) 47 +/- 8 45 +/- 8 - 69 +/- 8* -
Marie et al 1998 - 50 +/- 5 - 62 +/- 5* -
Marie et al 2001 - 50 +/- 5 51 +/- 8 57 +/- 5 65 +/- 8
Mean 41 45 63 -
*≥grade 2 rejectionJournal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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not well characterized and is essentially impossible to
study in a human population. The well recognized, and
not uncommon, entity of biopsy negative rejection sug-
gests that the sensitivity of endomyocardial biopsy is less
than 100%. Therefore disagreements between CMR and
biopsy may be a deficiency in CMR, endomyocardial
biopsy or both. The subgroup analysis by Marie et al. that
suggests that CMR might predict rejection in patients who
are CMR 'positive' and biopsy negative raises the exciting
possibility that CMR may be more sensitive than biopsy at
detecting rejection.
Limitations to T2 imaging
Signal dropout and motion artefacts are well recognized
problems affecting image quality in T2 weighted spin-
echo techniques. These pulse sequence deficiencies are
accentuated by low magnetic field strength, arrhythmia,
and long scan times. Most of the papers in the field of T2
imaging and transplant rejection predate the newer and
shorter Turbo Spin Echo (TSE) sequences and relied on
the much slower spin echo techniques with long scan
times. In addition many studies presented in this review
obtained their images using magnetic field strength well
below the current standard of 1.5 T, which yields lower
signal to noise ratios. Long scan times and low field
strength could both have had significant negative impact
on image quality. TSE sequences reduce scan times, but T2
quantification can be adversely affected by stimulated
echoes. TSE sequences are also sensitive to RF and static
field inhomogeneities [54]. T2 weighted images are prone
to signal gradation related to the proximity of the sampled
area to the acquisition coil. This has been largely corrected
with newer signal intensity correction algorithms, how-
ever some of the studies presented in this review used T2
weighted images that were likely subject to this potential
error. Biological factors may also affect T2 quantification
as many tissues types including the heart have been
shown to have multi-exponential T2 behaviour [55].
Under sampling the T2 decay curve can lead to a two fold
error in T2 estimation when multiexponential T2 behav-
iour is present[54].
He et al. have recently developed a T2 quantification
sequence for the purpose of measuring myocardial iron in
patients with thalassemia [56]. This novel spin-echo tech-
nique has since been installed and validated at four other
international centres [57]. The coefficient of variation for
local inter-study and inter-site variability was reported as
4.4% and 5.2%, respectively.
Despite the limitations of T2 weighted imaging men-
tioned above, previous work in transplant rejection stud-
ies has shown a consistent linear association between T2
relaxation times and the degree of acute transplant rejec-
tion. Furthermore, the relatively mild degree of rejection
detectable with this technique (i.e. grade 2 ISHLT 1990)
would not even require therapy in many contemporary
transplant settings. This suggests that the relationship
between T2 relaxation and rejection is highly sensitive and
very unlikely to miss any cases of advanced rejection.
Improvements in T2 imaging in the current era such as
higher field strengths, fast TSE sequences, and improved
blood and fat suppression techniques will likely
strengthen the association between T2 relaxation times
and transplant rejection[49].
T1 weighted CMR
Myocardial T1 signal intensity
T1 weighted cardiovascular MR images are influenced by
myocardial water content, although to a lesser extent than
T2 weighted images. Non-contrast enhanced T1 signal
intensity has shown an inconsistent correlation with rejec-
tion in animal models of heart transplantation [42,45].
Nishimura et al. used eight heterotopically transplanted
dogs to show that T1 signal intensity was increased with
rejection in a graded fashion that correlated with the
degree of rejection [45]. Similar trials did not confirm
these results [29,42]. Revel et al. assessed the utility of T1
signal intensity to diagnose rejection in 29 human heart
transplant recipients and found no significant correlation
with rejection as diagnosed by endomyocardial biopsy
[38].
Myocardial T1 quantification
The T1 relaxation time can be calculated from a series of
images acquired with an increasing delay following an
inversion or saturation of the magnetization. A longer
time of recovery is represented by larger T1 values, and
like T2 values, this typically reflects an environment of
fewer restrictions to water motion, such as edema. Aherne
et al. and Nishimura et al. used a dog model to show that
T1 relaxation times are prolonged in rejecting hearts com-
pared to non-rejecting hearts [29,45]. Animal spectros-
copy studies have also shown a significant prolongation
of T1 relaxation times with rejection [30,40].
Wisenberg et al. investigated 25 human heart transplant
recipients and found that mean T1 relaxation times were
significantly prolonged for those with rejection compared
to non-rejectors (497 ± 30 ms vs. 360 ± 21 ms, p < 0.05)
[33]. In this study, both T1 and T2 relaxation times were
only correlated with biopsy proven rejection after 24 days
post transplantation. As with T2 relaxation time, T1 relax-
ation time within the first 24 days post transplantation are
presumably influenced by perioperative factors unrelated
to rejection.
The relationship between T1 relaxation and transplant
rejection has been less well studied than that of T2 relaxa-
tion. The superior sensitivity to water content of T2Journal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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weighted imaging makes it a better choice for imaging
myocardial inflammation, and likely accounts for the




Gadolinium based contrast agents are by far the most
common contrast agents used in clinical CMR imaging.
Intravenous gadolinium increases signal intensity on T1
weighted images acquired early after contrast administra-
tion, in proportion to the degree of tissue perfusion and is
thought to reflect the hyperemia seen in inflamed tissue.
Increase in signal intensity early after contrast injection
(early enhancement) has shown utility in the diagnosis of
other disorders of myocardial inflammation such as myo-
carditis [26]. Abdel-Aty et al. found that early enhance-
ment alone was too insensitive for diagnosing
myocarditis, but was useful when used in combination
with T2 values and late gadolinium enhancement in a
scoring system for the diagnosis of myocarditis [26].
Yoshida et al. used a non-working allograft heart trans-
plant model in dogs to demonstrate a 25–42% increase in
signal intensity post gadolinium in rejecting allografts
compared to native hearts [58]. Konstam et al. showed
that T1 weighted maximal myocardial signal intensity
post gadolinium infusion could identify three distinct
grades of rejection in a rat model [59].
In two human trials of transplant rejection, post contrast
signal intensity tended to increase with degree of rejection
although it could not consistently identify the full spec-
trum of abnormal endomyocardial biopsies diagnostic of
rejection [35,36]. Alemnar et al. tested several variables of
contrast enhanced myocardial signal intensity in 40 heart
transplant patients and found no association with rejec-
tion[35]. Mousseaux et al. examined 39 heart transplant
patients for an association between biopsy proven rejec-
tion and myocardial enhancement (post contrast myocar-
dial SI – pre contrast myocardial SI/pre contrast
myocardial SI) within ten minutes post gadolinium injec-
tion [36]. They found an increase in myocardial enhance-
ment in rejectors compared with non-rejectors (mean
enhancement: grade 1 rejection = 70 +/- 14%, grade 2 or
3 rejection = 81 +/- 27%, non-rejectors 53% +/- 24, p <
0.05). However, myocardial enhancement was not able to
discriminate rejection severity [36].
Ventricular Wall Thickness and Systolic function
The correlation between biopsy proven rejection and
echocardiographically determined ventricular morphol-
ogy is specific in severe cases of acute cellular rejection but
is too insensitive to be used as a screening tool [60]. It has
been postulated that the superior spatial resolution of
CMR may lead to improved sensitivity in diagnosing
rejection on the basis of changes to ventricular morphol-
ogy [23].
Myocardial wall thickness has been shown to increase in
both animal [41,61] and human [33,38] CMR trials of
transplant rejection. Several animal studies showed that
increased wall thickness during acute rejection was corre-
lated to ex-vivo total myocardial water content
[29,30,40,62]. Wall thickness was not capable of accu-
rately identifying the severity of a rejection episode.
Revel et al. studied 29 heart transplant patients using CMR
and found that wall thickness increased during acute
rejection and decreased as the rejection episode resolved
[38]. Wisenberg also showed that left ventricular wall
thickness was increased in patients with rejection (ISHLT
≥ grade 2) compared to those without rejection (21 mm
vs. 13 mm) [33]. Alemnar et al. performed CMR on 40
transplant patients receiving contemporary anti-rejection
therapies and found no significant differences in ventricu-
lar volume, wall thickness, and ejection fraction between
those with and without histologic evidence of rejection
[35]. In the late 1990s, animal trials by Yoshida and Wal-
poth found that hearts undergoing rejection had reduced
ejection fraction and stroke volume, although these
changes were only significant when rejection was moder-
ate or severe [61,62].
Changes in ventricular morphology and systolic function
as measured by CMR are associated with rejection
[60,63,64]. Despite the excellent spatial resolution of
CMR, these variables are probably of insufficient sensitiv-
ity to detect the early and milder forms of rejection that
are of clinical interest.
Potential CMR Correlates of Heart Transplant Rejection
Diastolic Dysfunction
Diastolic dysfunction is one of the earliest measurable fea-
tures of heart transplant rejection [65]. Yoshida et al. used
a working heart model of untreated, syngenic and allo-
genic heart transplants in rats to assess left ventricular end
diastolic pressure volume relationship (LVEDPVR) [62].
Invasive catheterization was used to modulate cardiac
preload and measure pressures. CMR was used to assess
ventricular volumes. These data were then compiled into
LVEDPVR curves for various time points during rejection.
At four days post transplant, the untreated allograft group
showed a significant reduction in compliance compared
to the isograft group. The reduction in compliance pre-
ceded any evidence of systolic dysfunction. Despite these
provocative results, there have been no human studies
assessing CMR measures of diastology in Transplant rejec-
tion. Measuring diastolic function with CMR may
improve sensitivity in diagnosing rejection, however work
in this area would need to differentiate changes in diasto-Journal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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lic properties due to rejection and those due to the fibrotic
and hypertrophic remodeling that accompanies heart
transplantation even in the absence of rejection[66].
Twisting Mechanics
Left ventricular twisting mechanics have also been studied
in normal and transplanted hearts. Using magnetic reso-
nance tagging, Donofrio et al. found that non-rejecting
pediatric transplanted hearts had normal strain measure-
ments, but abnormal torsion patterns compared to nor-
mal hearts[67]. There were no episodes of rejection in this
study, thus differences between rejectors and non-reject-
ors could not be assessed.
Hansen et al. used implanted radio-opaque intramyocar-
dial markers and biplane fluoroscopy to serially study
twist and untwist in 12 heart transplant recipients [68].
They found a 25% decrease in torsional deformation
amplitude and peak systolic torsion during periods of
rejection compared to pre-rejection values. Despite vali-
dated techniques for CMR to quantify myocardial strain
and torsion, there have been no trials correlating CMR
measures of twisting mechanics and transplant rejection.
Late Gadolinium Enhancement
Gadolinium can also be used in CMR to detect areas of
myocardial scar or myocardial fibrosis. The rate at which
gadolinium is cleared from the myocardium is slower in
areas with fibrosis compared to healthy myocardium. T1
weighted images taken several minutes ("late") after con-
trast injection will show higher concentrations of gadolin-
ium in areas of myocardial fibrosis making these areas
appear bright. Late gadolinium enhancement (LGE) has
correlated well to pathologic assessment of myocardial
fibrosis in ischemic [69,70] and non-ischemic [26,71,72]
myocardial injury. A recent study of LGE patterns in heart
transplant patients found that 50% of patients had a non-
ischemic LGE pattern similar to that seen in diseases of
myocardial inflammation such as myocarditis[73]. No
study to date has looked at presence, degree, or location of
LGE patterns in acute human heart transplant rejection.
T1 and T2 Contrast Agent
Iron oxide particles
Iron oxide contrast agents have been used in clinical and
experimental MR since the 1980s predominantly in the
field oncology [74-76]. More recently, these agents have
been shown to be safe [77] and useful for contrast MR
angiography[78,79]. Iron oxide contrast agents contain
superparamagnetic particles with an iron oxide crystal
core wrapped in an outer coating (i.e. dextran) which
shorten both T1 and T2/T2* relaxation [80]. Over time,
iron oxide particles are taken up by macrophages which
shortens their T2/T2* properties. Thus, accumulation of
macrophages, which contain iron oxide, in inflamed tis-
sue can be visualized as a signal loss on T2 weighted
images.
Kanno et al. showed that T2 signal intensity decreased 24
hours after iron oxide particle injection in untreated rat
allografts compared to isografts at day seven (SI: 95% vs.
70%) [81]. Signal intensity in rejecting allografts returned
to baseline after treatment with cyclosporine for seven
days. Immunohistochemistry confirmed accumulation of
iron oxide containing macrophages in areas of rejection
[81].
Iron oxide contrast agents have also been used in a rat
model of cardiac transplant rejection to study hyperemia.
Immediately after injection, iron oxide particles remain
intravascular unless there are alterations in local vascular
permeability as seen in inflamed tissue. Extravasation of
iron oxide particles leads to an increase in signal intensity
in these regions on T1 weighted images. Johansson et al.
showed that six days post transplant, T1 signal intensity
was increased in untreated rat allografts compared to iso-
grafts within 5 minutes of iron oxide injection (mean dif-
ference 25%)[82]. Penno et al. used a T1 weighted 3-D
spoiled gradient echo sequence to show that myocardial
signal intensity in rejecting rat allografts was significantly
elevated compared to immunosuppressed allografts
within four minutes post contrast injection[83]. Treat-
ment of the rejection episode reversed the increase in sig-
nal intensity. The rapidity of the change in signal intensity
suggests altered vascular permeability is responsible for
the increase in signal.
CMR with iron oxide particles is a novel and potentially
powerful method to evaluate inflammation in the heart.
T1 Imaging early post iron oxide contrast injection can
identify increased vascular permeability, while delayed T2
imaging gives information into in-vivo macrophage accu-
mulation. Human trials of transplant rejection and iron
oxide contrast agents are needed.
Conclusion
Several CMR variables have shown good correlation to
biopsy proven heart transplant rejection, the strongest of
which is quantitative T2 assessment. Criticism regarding
the reproducibility of T2 measures[84] as well as limited
access to CMR have likely hampered the adoption of CMR
into routine post transplant clinical care. Improvements
in CMR hardware combined with appropriate pulse
sequences for T2 quantification makes routine ascertain-
ment of T2 relaxation more feasible [56,57] and improves
inter-center reproducibility over traditional T2 results
based on signal intensity. Early enhancement may also
prove useful in diagnosing transplant rejection just as it
has in the diagnosis of myocarditis. Studies are needed to
evaluate promising CMR correlates of rejection such asJournal of Cardiovascular Magnetic Resonance 2009, 11:7 http://www.jcmr-online.com/content/11/1/7
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diastolic function, ventricular twist, late gadolinium
enhancement, and paramagnetic iron oxide contrast
agents. Future studies should focus on combining multi-
ple CMR measures into a transplant rejection scoring sys-
tem to improve the sensitivity in detecting heart
transplant rejection and possibly reduce, if not eliminate,
the need for endomyocardial biopsy.
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